Skip to content

13F-HR filed by Patient Square Capital LP

Patient Square Capital LP filed this 13F-HR for the quarter ended 2026-03-31, filed 2026-05-15, with 29 holding rows worth $563,607,117.

Accession
0001819257-26-000003
Filed
2026-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2026

A holdings report, 29 entries on the cover page, a total value of $563,607,117 stated on the cover page (in dollars after the unit check, H1), rows summing to $563,607,117 with VALUE read as dollars as filed, 13F file number 028-22927. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ROIVANT SCIENCES LTDG76279101SHS8,166,047$226,199,502dollars as filed
ARGENX SE SPONSORED ADR04016X101ADR36,718$26,813,320dollars as filed
INSMED INC COM PAR $.01457669307Stock157,500$25,754,400dollars as filed
BEONE MEDICINES LTD SPONSORED ADS07725L102ADR80,542$23,918,558dollars as filed
COGENT BIOSCIENCES INC19240Q201COM596,000$22,940,040dollars as filed
MIRUM PHARMACEUTICALS INC604749101COM230,000$21,247,400dollars as filed
BELITE BIO INC07782B104CMN116,684$18,604,097dollars as filed
LEGEND BIOTECH CORP52490G102SPONSORED ADS990,000$17,909,100dollars as filed
NEKTAR THERAPEUTICS640268306COMMON STOCK210,000$15,109,500dollars as filed
DBV TECHNOLOGIES S A23306J309SPONSORED ADS693,534$14,487,925dollars as filed
PHARVARIS NVN69605108COMMON STOCK493,000$13,927,250dollars as filed
ABIVAX SA-00370M103SPONSORED ADS121,245$13,500,631dollars as filed
XENON PHARMACEUTICALS INC COM98420N105Stock227,000$13,200,050dollars as filed
CELCUITY INC15102K100COM95,000$10,843,300dollars as filed
EYEPOINT INC COM NEW30233G209Stock795,000$10,247,550dollars as filed
Merck & Co.,Inc.58933Y105COM80,000$9,623,200dollars as filed
ARCUTIS BIOTHERAPEUTICS INC03969K108COM400,645$9,439,196dollars as filed
ALLOGENE THERAPEUTICS INC019770106COM3,450,000$8,418,000dollars as filed
KYMERA THERAPEUTICS INC501575104COM100,000$8,329,000dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM93,882$7,878,577dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock200,000$7,840,000dollars as filed
PERSPECTIVE THERAPEUTICS INC46489V302COMMON STOCK1,625,000$6,776,250dollars as filed
DEFINIUM THERAPEUTICS INC24477V105COM SHS331,000$6,255,900dollars as filed
HARROW INC415858109COM165,209$5,825,269dollars as filed
PROTARA THERAPEUTICS INC74365U107COM STK1,030,846$5,370,708dollars as filed
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK1,085,790$5,103,213dollars as filed
ARCUS BIOSCIENCES INC03969F109COM195,000$4,212,000dollars as filed
ASSEMBLY BIOSCIENCES INC045396207COMMON STOCK136,315$3,782,741dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW1,000$50,440dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001819257-26-000003this filing2026-05-15acceptance time not in the bulk data set